Abstract
There is growing research focusing on the sleep problems of children with attention-deficit/hyperactivity disorder (ADHD) in recent years. High incidence of sleep disorders in children with ADHD may be associated with a substantial impact on their quality of life and exacerbation of ADHD symptoms. The core symptoms of ADHD can be effectively treated by various medications, including methylphenidate (MPH), amphetamine, pemoline, and the newly FDA-approved extended-release α2 adrenergic agonists. However, most of them are known to affect patients' sleep because of their pharmacological actions on dopaminergic and/or noradrenergic release in the central nervous system. Previous studies have found increased incidence of insomnia and sleep disturbances in ADHD children treated with CNS (central nervous system) stimulants. In contrast, recent prospective, double-blind, placebo-controlled trials concluded that MPH, by objective polysomnographic or actigraphic measurements, did not cause significant sleep problems in children or adolescents with ADHD. Given the fact that sleep quality and core symptoms of ADHD are highly correlated, it is imperative that we understand the effects of ADHD medications on sleep while prescribing either CNS stimulants or non-CNS stimulants. Here we will concisely review the pharmacological treatments of ADHD, and provide the relevant data discussing their short- and long-term effects on sleep.
Keywords: Attention-deficit hyperactivity disorder, sleep, medication, comorbidity, stimulants, hyperactivity, exacerbation, methylphenidate, amphetamine, pemoline, noradrenergic, actigraphic, adolescents, pharmacokinetics, guanfacine, clonidine, latencies, psychiatric, nortriptyline
Current Pharmaceutical Design
Title: Pharmacological Treatment of ADHD and the Short and Long Term Effects on Sleep
Volume: 17 Issue: 15
Author(s): Yu-Shu Huang, Ming-Horng Tsai and Christian Guilleminault
Affiliation:
Keywords: Attention-deficit hyperactivity disorder, sleep, medication, comorbidity, stimulants, hyperactivity, exacerbation, methylphenidate, amphetamine, pemoline, noradrenergic, actigraphic, adolescents, pharmacokinetics, guanfacine, clonidine, latencies, psychiatric, nortriptyline
Abstract: There is growing research focusing on the sleep problems of children with attention-deficit/hyperactivity disorder (ADHD) in recent years. High incidence of sleep disorders in children with ADHD may be associated with a substantial impact on their quality of life and exacerbation of ADHD symptoms. The core symptoms of ADHD can be effectively treated by various medications, including methylphenidate (MPH), amphetamine, pemoline, and the newly FDA-approved extended-release α2 adrenergic agonists. However, most of them are known to affect patients' sleep because of their pharmacological actions on dopaminergic and/or noradrenergic release in the central nervous system. Previous studies have found increased incidence of insomnia and sleep disturbances in ADHD children treated with CNS (central nervous system) stimulants. In contrast, recent prospective, double-blind, placebo-controlled trials concluded that MPH, by objective polysomnographic or actigraphic measurements, did not cause significant sleep problems in children or adolescents with ADHD. Given the fact that sleep quality and core symptoms of ADHD are highly correlated, it is imperative that we understand the effects of ADHD medications on sleep while prescribing either CNS stimulants or non-CNS stimulants. Here we will concisely review the pharmacological treatments of ADHD, and provide the relevant data discussing their short- and long-term effects on sleep.
Export Options
About this article
Cite this article as:
Huang Yu-Shu, Tsai Ming-Horng and Guilleminault Christian, Pharmacological Treatment of ADHD and the Short and Long Term Effects on Sleep, Current Pharmaceutical Design 2011; 17 (15) . https://dx.doi.org/10.2174/138161211796197179
DOI https://dx.doi.org/10.2174/138161211796197179 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Microglia in the Pathogenesis of Sepsis-Associated Encephalopathy
CNS & Neurological Disorders - Drug Targets Mechanisms and Medical Management of Exercise Intolerance in Hypertrophic Cardiomyopathy
Current Pharmaceutical Design Medications Affecting Functional Status in Older Persons
Current Pharmaceutical Design Peptide Metabolism and the Control of Body Fluid Homeostasis
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Spontaneous Coronary Artery Dissection: Does Being Unemployed Matter? Insights from the GSCAD Registry
Current Cardiology Reviews Isolated Perioperative Hypertension: Clinical Implications & Contemporary Treatment Strategies
Current Hypertension Reviews Type 1 11 β-hydroxysteroid Dehydrogenase as Universal Drug Target in Metabolic Diseases?
Endocrine, Metabolic & Immune Disorders - Drug Targets Antiplatelet and Anticoagulation Strategies in the Prevention and Treatment of Ischemic Stroke
Current Pharmaceutical Design The Role of Natural Products in the Discovery of New Drug Candidates for the Treatment of Neurodegenerative Disorders I: Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Molecular Mechanisms Involved in the Control of Neurohypophyseal Hormones Secretion
Current Pharmaceutical Design Novel Neuroendocrine and Metabolic Mechanism Provides the Patented Platform for Important Rejuvenation Therapies: Targeted Therapy of Telomere Attrition and Lifestyle Changes of Telomerase Activity with the Timing of Neuron-Specific Imidazole-Containing Dipeptide-Dominant Pharmaconutrition Provision
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Oleanolic Acid and Related Triterpenoids from Olives on Vascular Function: Molecular Mechanisms and Therapeutic Perspectives
Current Medicinal Chemistry Preface [Hot Topic: Chromogranin A and Its Derived Peptides as Potential Regulators of Immune, Endocrine and Metabolic Systems - In Search of Its Physiological Role (Guest Editors: K.B. Helle and G. Serck-Hanssen)]
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents The Emerging Role of Helicobacter Pylori-Induced Metabolic Gastrointestinal Dysmotility and Neurodegeneration
Current Molecular Medicine Pharmacological Evidence of α -adrenergic Receptors in the Hypotensive Effect of Chamaemulum nobile L.
Cardiovascular & Hematological Agents in Medicinal Chemistry A Review of the Cardiovascular and Anti-Atherogenic Effects of Ghrelin
Current Pharmaceutical Design Risk of Bleeding Related to Antithrombotic Treatment in Cardiovascular Disease
Current Pharmaceutical Design Naturally Occurring Hydroxytyrosol: Synthesis and Anticancer Potential
Current Medicinal Chemistry Peptide Therapeutics in Neurodegenerative Disorders
Current Medicinal Chemistry Pharmacogenetics of the Human MDR1 Multidrug Transporter
Current Pharmacogenomics